Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings as of May 17, 2018

May 17, 2018 - By Tina Gentry

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

A total of 5 analysts rate Celldex (NASDAQ:CLDX) as follows: 1 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 20% are bullish. (NASDAQ:CLDX) has 5 ratings reports on May 17, 2018 according to StockzIntelligence. The company rating was maintained by WBB Securities on Wednesday, December 6. On Tuesday, April 17 Cantor Fitzgerald maintained the shares of CLDX in report with “Neutral” rating. On Thursday, March 8 the rating was maintained by Leerink Swann with “Market Perform”. The stock rating was maintained by Jefferies with “Hold” on Thursday, March 8. On Monday, April 16 Cowen & Co downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) to “Hold” rating. Listed here are Celldex Therapeutics, Inc. (NASDAQ:CLDX) PTs and latest ratings.

17/04/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $9 New Target: $3 Maintain
16/04/2018 Broker: Cowen & Co Rating: Hold Downgrade
08/03/2018 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain
08/03/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $4 New Target: $3 Maintain
06/12/2017 Broker: WBB Securities Rating: Buy New Target: $10.0 Maintain

The stock decreased 1.02% or $0.0071 during the last trading session, touching $0.6902.Currently Celldex Therapeutics, Inc. is downtrending after 30.36% change in last May 17, 2017. CLDX has also 812,203 shares volume. CLDX underperformed the S&P500 by 41.91%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics.The firm is worth $98.97 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer.Currently it has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Another two news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were recently brought out by: Seekingalpha.com on April 19, 2018 with title “Celldex Nearly Back To Square One”. The other Globenewswire.com‘s article was titled “Celldex Provides Corporate Update and Reports First Quarter 2018 Results” and brought out on May 10, 2018.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.